The global vancomycin market is projected to increase from a valuation of US$ 313.7 Mn in 2020 to US$ 465.1 Mn by the end of 2027. Demand for vancomycin to expand at a CAGR of 5.8% during the forecast period. Vancomycin demand is predicted to grow due to rising prevalence of infectious diseases, increased awareness programs, and government financing for the research and development of new treatments. The market is predicted to expand at a 5.8% CAGR from 2021 to 2027.
The offer in this portion accompanies many open doors including fabricating items, appropriation, retail, and showcasing administrations. Broad rounds of essential and far reaching optional exploration have been utilized by the examiners at Fact.MR to show up at different assessments and projections for Demand of Vancomycin Market both at worldwide and provincial levels.
Download a Sample Copy of This Report: –
https://www.factmr.com/connectus/sample?flag=S&rep_id=7293
“Positive Mechanism of Vancomycin & Rising Investments in R&D Activities to Foster Market Expansion”
The bactericidal activity of vancomycin is mostly due to its reduction of cell-wall formation. It prevents N-acetylmuramic acid and N-acetylglucosamine peptide subunits from being incorporated into the peptidoglycan matrix, the most critical structural component of Gram-positive cell walls.
Vancomycin forms hydrogen bonds with D-alanyl-D-alanine moieties at the end of the peptide, preventing them from being integrated into the peptidoglycan matrix. It also has an impact on bacterial cell membrane permeability and RNA synthesis.
No cross-resistance occurs between vancomycin and other antibiotic medications. Vancomycin does not have any effect on gram-negative bacteria, mycobacteria, or even fungi in vitro.
The global vancomycin industry is growing as antibiotic consumption rises in low- and middle-income nations, with pharmaceutical companies investing heavily in research and development, besides the rising prevalence of infectious diseases.
Recent Industry News
The vancomycin market has witnessed notable developments and announcements. In 2022, researchers made a breakthrough in vancomycin’s structure, potentially paving the way for the development of even more potent versions of the drug. Scientists at The Scripps Research Institute modified vancomycin’s structure to increase its efficacy against resistant bacteria. This discovery holds promise for addressing the evolving landscape of antibiotic resistance.
Additionally, regulatory agencies have been actively involved in overseeing the vancomycin market. In the same year, the U.S. Food and Drug Administration (FDA) issued new guidelines to encourage the development of improved antibiotics, including those targeting Gram-positive infections. These guidelines aim to streamline the approval process for novel antibiotics, incentivizing pharmaceutical companies to invest in research and development efforts.
Market Players: –
- Alvogen
- MGB Biopharma Limited
- Oragenics
- Aphios Corporation
- Microbiotix
Competitive Landscape
Vancomycin is a competitive and moderately fragmented market. There are many players in the sector under scrutiny, including both, small and large pharmaceutical companies. Furthermore, a wave of early-stage biotech companies has entered the market in response to developing antibiotic resistance.
For instance :
- In February 2022, Magnolia Medical Technologies, Inc., the producer of Steripath®, which is the only FDA 510(k)-complaint device platform for the reduction of blood culture contamination for sepsis testing1, revealed US$ 46 million of growth equity financing led by RTW Investments, LP (“RTW”), and Sectoral Asset Management.
Key Segments Covered in Vancomycin Industry Research
- Vancomycin Market by Type :
- Daptomycin
- Linezolid
- Quinupristin
- Ampicillin
- Chloramphenicol
- Others
- Vancomycin Market by Application :
- Sepsis
- Lung Infection
- Skin Soft Tissue Infection
- Colitis & Intestinal Inflammation
- Other Infections
Regional analysis includes
- North America (U.S., Canada)
- Latin America (Brazil, Mexico, Argentina, Chile, Peru, Rest of LATAM)
- EU – (Germany, France, Italy, Spain), UK, BENELUX (Belgium, Netherlands, Luxemburg), NORDIC (Norway, Denmark, Iceland, Sweden), Eastern Europe (Poland, Ukraine, Czech Rep. etc.), Rest of Europe
- CIS & Russia
- Japan
- Asia Pacific Excluding Japan (Greater China, India, S. Korea, ASEAN Countries, Rest of APEJ)
Customize this report for your specific research solution:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=7293
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E Mail : [email protected]